Seattle, Washington’s ZymoGenetics will cut 161 employees and discontinue research on cancer treatments. The firm will continue to market its only approved product, the blood-clotting compound Recothrom Thrombin, and will narrow its research focus to immunology. ZymoGenetics said the terminated employees will get severance benefits. ZymoGenetics is a biotechnology and pharmaceutical firm involved in the development of therapeutic [...]
Continue reading...
Wednesday, April 29, 2009
0 Comments